Irinotecan
Cutaneous T-cell Lymphoma Stage I
University of WashingtonSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Cutaneous T-cell Lymphoma Stage I cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Triamcinalone Rochester Skin Lymphoma Medical Group, PLLC | Phase 2 | B |
Valchlor Rochester Skin Lymphoma Medical Group, PLLC | Phase 2 | B |
Mechlorethamine Rochester Skin Lymphoma Medical Group, PLLC | Phase 2 | B |
(+)-VINCRISTINE University of Washington | Phase 2 | CCC |
Vorinostat University of Washington | Phase 2 | CCC |
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →